Aveanna Healthcare (AVAH) Projected to Post Earnings on Thursday

Key Points

• Aveanna Healthcare (AVAH) is set to report its Q2 2025 quarterly earnings on August 7th, with analysts predicting earnings of $0.04 per share and revenue of $535.34 million.
• The company recently saw its stock price decline by 0.7%, opening at $3.99. Its market capitalization stands at $778.41 million, with a P/E ratio of 199.50.
• A number of recent analyst reports have led to varying ratings for Aveanna Healthcare, including upgrades to "buy" from Jefferies and a target price increase to $5.00 by UBS Group.

Aveanna Healthcare (NASDAQ:AVAH - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $535.34 million for the quarter.

Aveanna Healthcare Stock Up 2.5%

AVAH traded up $0.10 during trading on Monday, reaching $3.84. The stock had a trading volume of 148,523 shares, compared to its average volume of 374,996. The stock has a 50 day moving average of $4.67 and a two-hundred day moving average of $4.80. Aveanna Healthcare has a 1-year low of $2.61 and a 1-year high of $6.19. The firm has a market capitalization of $748.17 million, a price-to-earnings ratio of 191.75 and a beta of 1.95.

Insider Transactions at Aveanna Healthcare

In other news, major shareholder J.H. Whitney Equity Partners V sold 750,000 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $5.20, for a total transaction of $3,900,000.00. Following the completion of the transaction, the insider directly owned 28,890,756 shares in the company, valued at $150,231,931.20. The trade was a 2.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Paul R. Vigano sold 750,000 shares of the stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $5.20, for a total transaction of $3,900,000.00. Following the completion of the sale, the insider directly owned 28,890,756 shares of the company's stock, valued at approximately $150,231,931.20. This trade represents a 2.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 7,115,345 shares of company stock worth $37,838,057. Insiders own 7.00% of the company's stock.

Institutional Trading of Aveanna Healthcare

Institutional investors and hedge funds have recently modified their holdings of the company. AQR Capital Management LLC raised its stake in Aveanna Healthcare by 21.2% during the first quarter. AQR Capital Management LLC now owns 26,280 shares of the company's stock worth $142,000 after acquiring an additional 4,602 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Aveanna Healthcare by 8.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 339,853 shares of the company's stock worth $1,842,000 after purchasing an additional 25,974 shares during the last quarter. Finally, Jane Street Group LLC increased its position in shares of Aveanna Healthcare by 522.0% during the 1st quarter. Jane Street Group LLC now owns 75,081 shares of the company's stock worth $407,000 after purchasing an additional 63,010 shares in the last quarter. 87.96% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

AVAH has been the subject of a number of research reports. Truist Financial reduced their target price on shares of Aveanna Healthcare from $6.00 to $5.00 and set a "hold" rating for the company in a report on Wednesday, July 16th. UBS Group upped their price target on Aveanna Healthcare from $4.50 to $5.00 and gave the company a "sell" rating in a research report on Friday, May 9th. Wall Street Zen downgraded Aveanna Healthcare from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 27th. Barclays started coverage on Aveanna Healthcare in a report on Wednesday, July 2nd. They set an "equal weight" rating and a $5.50 target price on the stock. Finally, Jefferies Financial Group upgraded Aveanna Healthcare from a "hold" rating to a "buy" rating and decreased their price target for the stock from $6.25 to $6.00 in a research note on Monday, July 21st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Aveanna Healthcare presently has a consensus rating of "Hold" and a consensus price target of $5.25.

About Aveanna Healthcare

Aveanna Healthcare Holdings Inc, a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities.